Dermatologic Manifestations of Aspergillosis Treatment & Management
- Author: Annie Chiu, MD; Chief Editor: William D James, MD more...
In both disseminated and limited cutaneous aspergillosis, high-dose intravenous amphotericin B, in traditional or liposomal form has been the traditional antifungal used to eradicate the underlying organism. However, voriconazole is also approved as a first-line agent for aspergillosis and is being used with increased frequency. Other treatment options for aspergillosis include itraconazole, caspofungin, or voriconazole in combination with terbinafine.[9, 10, 11] Topical voriconazole solution combined with a systemic antifungal has also been reported as effective for secondary cutaneous aspergillosis. For Aspergillus -induced onychomycosis, treatment is with oral itraconazole because topical medications have very limited efficacy in eradicating fungus from the nail.
From a more homeopathic standpoint, a recent study showed in vitro antifungal activity of essential oil of Juniperus communis against A flavus, A fumigatus, and A niger.
In the case of secondary wound infection of the scalp with A niger, treatment with ketoconazole 2% gel and retapamulin ointment resulted in resolution of the nonhealing wound.
Also see the clinical guideline summary, Treatment of Aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.
The following is a selection of active, recruiting, or completed clinical trials:
Several case reports have documented the effectiveness of surgical excision or debridement in the treatment of primary cutaneous aspergillosis. Some of the patients also received concurrent or subsequent systemic antifungal therapy.
See the list below:
- Consult a dermatologist for diagnosis, excision, and wound care.
- Consult an infectious diseases specialist for treatment recommendations in the setting of systemic disease.
Ozer B, Kalaci A, Duran N, Dogramaci Y, Yanat AN. Cutaneous infection caused by Aspergillus terreus. J Med Microbiol. 2009 Jul. 58:968-70. [Medline].
Zhang QQ, Li L, Zhu M, Zhang CY, Wang JJ. Primary cutaneous aspergillosis due to Aspergillus flavus: a case report. Chin Med J (Engl). 2005 Feb 5. 118(3):255-7. [Medline].
Mohapatra S, Xess I, Swetha JV, et al. Primary cutaneous aspergillosis due to Aspergillus niger in an immunocompetent patient. Indian J Med Microbiol. 2009 Oct-Dec. 27(4):367-70. [Medline].
Larkin JA, Greene JN, Sandin RL, Houston SH. Primary cutaneous aspergillosis: case report and review of the literature. Infect Control Hosp Epidemiol. 1996 Jun. 17(6):365-6. [Medline].
Robinson A, Fien S, Grassi MA. Nonhealing scalp wound infected with Aspergillus niger in an elderly patient. Cutis. 2011 Apr. 87(4):197-200. [Medline].
Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis. Mycoses. 1994 Jul-Aug. 37(7-8):271-4. [Medline].
Kim CW, Seo JS, Kim MK, Jun EJ, Choi JC, Choi BW. Secondary cutaneous aspergillosis disseminated from the lungs of a patient with asthma on 1 month steroid treatment. Diagn Microbiol Infect Dis. 2010 Jan. 66(1):104-7. [Medline].
Wheat LJ. Rapid diagnosis of invasive aspergillosis by antigen detection. Transpl Infect Dis. 2003 Dec. 5(4):158-66. [Medline].
Krishnan-Natesan S, Chandrasekar PH, Manavathu EK, Revankar SG. Successful treatment of primary cutaneous Aspergillus ustus infection with surgical debridement and a combination of voriconazole and terbinafine. Diagn Microbiol Infect Dis. 2008 Dec. 62(4):443-6. [Medline].
Cooke FJ, Terpos E, Boyle J, Rahemtulla A, Rogers TR. Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. Clin Microbiol Infect. 2003 Dec. 9(12):1238-41. [Medline].
Koss T, Bagheri B, Zeana C, Romagnoli MF, Grossman ME. Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. J Am Acad Dermatol. 2002 Jun. 46(6):945-7. [Medline].
Klein KC, Blackwood RA. Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant. Pediatrics. 2006 Aug. 118(2):e506-8. [Medline].
Cabral C, Francisco V, Cavaleiro C, et al. Essential Oil of Juniperus communis subsp. alpina (Suter) Celak Needles: Chemical Composition, Antifungal Activity and Cytotoxicity. Phytother Res. 2012 Feb 1. [Medline].
[Guideline] Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008 Feb 1. 46(3):327-60. [Medline].
Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002 Aug 8. 347(6):408-15. [Medline].
Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis. 2007 Jan 1. 44(1):2-12. [Medline].
Elder D, Elenitsas R, Jaworsky C, eds. Lever's Histopathology of the Skin. Philadelphia, Pa: Lippincott-Raven; 1997. 525-6.
Freedberg I, Eisen AZ, Wolff K, et al, eds. Fitzpatrick's Dermatology in General Medicine. 5th ed. New York, NY: McGraw-Hill; 1999. 1436-7.
Odom RB, James WD, Berger TG, eds. Andrews' Diseases of the Skin. Philadelphia, Pa: WB Saunders; 2000. 415.
Richardson MD, Warnock DW, eds. Fungal Infection. Diagnosis and Management. 2nd ed. Blackwell Science: Oxford, England; 1997. 113-30.